biotech
biotech at Beyond Market Intelligence is a file of 6 stories. The newest of them: “A simple saliva test aligns cancer care with your body's internal clock”, “Mining copper for the AI era gets a biomolecular boost”, and “Evvy secures $40M to advance women's health through microbiome data”. Your treatment plan shouldn't ignore what time it is for your body. Copper is the quiet backbone of the AI era, and Giraffe Bio just gave it a biomolecular upgrade. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every biotech story on Beyond Market Intelligence, newest first.
A simple saliva test aligns cancer care with your body's internal clock
Your treatment plan shouldn't ignore what time it is for your body. German startup TimeTeller has developed a simple saliva test kit that decodes your circadian rhythm, helping oncologists align cancer care with your internal clock. The goal is straightforward: fewer side effects, better outcomes. It's a practical, human-centered step toward making precision medicine feel less abstract. For more on biomolecular innovation, see our coverage of Giraffe Bio's copper-mining breakthrough.
Mining copper for the AI era gets a biomolecular boost
Copper is the quiet backbone of the AI era, and Giraffe Bio just gave it a biomolecular upgrade. With $6.4 million in seed funding, the company is helping miners extract more of this essential mineral, no small feat when AI data centers and EVs are driving demand through the roof. This isn't about hype; it's about making extraction smarter. For deeper context on the forces behind this surge, read "The Real Question Behind AI Data Centers Is Who Decides."
Evvy secures $40M to advance women's health through microbiome data
Evvy just raised $40 million in a Series B round led by Catalio Capital Management, and that's a meaningful vote of confidence for a company putting vaginal microbiome data at the center of women's health research. It's about time this kind of data got serious backing. The funding can accelerate discoveries that have been underfunded for too long. If you're tracking how capital is moving through health innovation, this pairs well with our coverage on Wahlberg and Lee discussing wellness at Disrupt 2026.
Discover the startups VCs are betting on to transform data and beyond.
VCs have spoken, and the summer batch of Y Combinator startups is as ambitious as it gets. From floating reactors to brain chips, the picks reflect a clear appetite for moonshot thinking. It is a compelling signal that investors are betting on transformative potential, not just incremental improvements. For a deeper dive into how AI is reshaping infrastructure, check out our piece on Nscale's $3.36B commitment to AI-native data centers. The future is being built now, and it is worth exploring.
Why open data, not moats, will let AI engineer better medicine
Vijay Pande walked away from managing $4 billion at a16z to bet smaller, and that restraint is exactly the point. His new firm, VZVC, leans into AI-native investing because he sees biology shifting from discovery to engineering. Clinical trials remain brutally expensive, and he argues open, shared datasets will matter more than proprietary walls. That conviction feels right. For a deeper look at how AI handles messy real-world data, our piece on real-world computer vision deployments is worth reading.
A vision-restoring implant earns EU approval, opening new data frontiers.
Science Corp.'s vision-restoring chip just cleared EU approval, and CEO Max Hodak's take cuts straight to the point: the field needs a company pulling in real revenue, not just promising headlines. That pragmatism is exactly what this space has lacked. It's one thing to build transformative tech; it's another to make it sustainable enough to matter. For anyone watching how AI-native tools reshape industries, this is a signal worth exploring.